Medical terapy of multinodular goitre;La terapia medica del gozzo multinodulare

Annali Italiani di Chirurgia

Volumn 67, Issue 3, 1996, Pages 327-334

  Giordano, G ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Goitre; Growth factors; Hypothyroidism; Thyroid disease; Thyroid hormones

Indexed keywords

THYROID HORMONE; THYROTROPIN;

FEMALE; HUMAN; MALE; NODULAR GOITER; REVIEW; SECRETION;

FEMALE; GOITER, NODULAR; HUMANS; MALE; THYROID HORMONES; THYROTROPIN;

EID: 0030133147     PISSN: 2239253X     EISSN: 2239253X     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Anderson P.E., Hurley P.R., Rosswick P.: Conservative treatment and long term prophylactic thyroxine in the prevention of recurrence of multinodular goiter. Surg Gynecol Obstet, 171:309-314.
2. Badillo J., Shimaoka K., Lessmann E.M., Marchetta F.C., Sokal J.E.: Treatment of nontoxic goiter with sodium liothyronine. A double-blind studiy. JAMA, 184: 151-158, 1963 (da Cooper (12)).
3. Bartalena L., Brogioni S., Grasso L., Martino E.: Interleukin-6 and the thyroid. Europ J Endocr, 132, 386-393, 1995.
4. Bartalena L., Martino., Pacchiarotti A., Aghini-Lombardi F., Buratti L., Bambini G., Breccia M., and Pinchera P.: Factors affecting suppression of endogenous thyrotropin secretion by thyroxine treatment: retrospective analysis in athyreotic and goitrous patients. J Clin Endocrinol Metab, 64:849-855, 1987.
5. Bergfelt G., Risholm L.: Postoperative thyroid hormone therapy in nontoxic goitre. Acta Chir Scand, 126:531-537, 1963.
6. Berglund J., Bondensson L., Christensen S.B., Larsson A.S., Tibblin S.: Indications for thyroxine therapy after surgery for non-toxic benign goitre. Acta Chir Scand, 156:433-438, 1990.
7. Bongers H., Hotze L.A., Schimitz R., Joseph K.: LT4-monopre-paration versus LT4-LT3-compound preparation in the treatment of diffuse endemic goitre. Acta Endocrinol (Copenh), 113:242-248, 1986.
8. Bronnegard M., Torring O., Boos J., Sylven C., Marcus C. and Walling G.: Expression of thyrotropin receptor and thyroid hormone receptor messenger ribonucleic acid in normal hyperplastic, and neoplastic human thyroid tissue. J Clin Endocrinol Metab, 79:384-389, 1994.
9. Brown R.S.: Immunoglobulins affecting thyroid growth: a continuing controversy. J Clin Endocrinol Metab, 80, 5: 1506-1508, 1995.
10. Celani M.F., Mariani M., Mariani G.: On the usefulness of levothyroxine suppressive therapy in the medical treatment of benign solitary, solid or predominantly solid, thyroid nodules. Acta Endocrinol (Copenh), 123:603-608, 1990.
11. Cheung P.S.Y., Lee J.M.H., Boey J.H.: Thyroxine suppresive therapy of benign solitary thyroid nodules: a prospective randomized study. Word J. Surg, 13:818-822, 1989.
12. Cooper D.S.: Thyroxine suppression therapy for benign nodular disease. J Clin Endocrinol Metab, 80, 2: 331-334, 1995.
13. Crile G. Jr.: Endocrine dependency of papillary carcinomas of the thyroid. JAMA, 195:721-724, 1996.
14. Degroot L.J.: Diagnostic approach and management of patients exposed to irradiation to the thyroid. J Clin Endocrinol Metab, 69:925-928, 1989.
15. Drexhage H.A.: Immunoglobulins affecting thyroid growth. Thyroid Today, 8:1-5, 1985.
16. Feldt-Rasmussen U., Hegedus L., Hansen J., Perrild H.: Relationship between thyroid volume and serum thyroglobulin during long-term suppression with triiodothyroxine in patients with diffuse non-toxic goitre. Acta Endocrinol (Copenh), 105:184-189, 1984.
17. Filetti S., Belfiore A., Amir S.M. et al.: The role of thyroid-stimulating antibodies of Grave's disease in differentiated thyroid cancer. N Engl J Med, 318:753-779, 1988.
18. Fogelfeld L., Wiviott M.B.T., Freedman E.S., Blend M.B., Bekerman C, Pinsky S., Schneider A.B.: Recurrence of thyrod nodules after surgical removal in patients irradiated in childhood for benign conditions. N Engl J Med, 320:835-840, 1989.
19. Geerdsen J.P., Frolund L.: Thyroid function afier surgical treatment of nontoxic goitre. A randomized study of postoperative thyroxine administration. Acta Med Scand, 220:341-345, 1986.
20. Geerdsen J.P., Frolund L.: Recurrence of nontoxic goitre with and without postoperative thyroxine medication. Clin Endocrinol (Oxf), 21:529-533, 1984.
21. Gharib H., James E.M., Charboneau J.W., Naessens J.M., Offord K.P., Gorman C.A.: Suppressive therapy with levothyroxine for solitary thyroid nodules. A double-blind controlled clinical study. N Engl J Med, 317:70-75, 1987.
22. Goretzki P., Roeher H.D., Horeyseck G.: Prophylaxis of recurrent goiter by high-dose L-thyroxine. Word J. Surg, 5:855-857, 1981.
23. Gullino P.M.: Natural history of breast cancer. Progression from hyperplasia to neoplasia as predicted by angiogenesis. Cancer, 39:2697-2703, 1977.
24. Hamburger J.L.: Extensive personal experience. Diagnosis of thyroid nodules by fine needle biopsy. Use and abuse. J Clin Endocrinol Metab, 79:335-339, 1994
25. Hansen J.M., Kampmann J., Madsen S.N., Skovsted L., Solgaard S., Grytter C., Grontvedt T., Rasmussen S.N.: L-Thyroxine treatment of diffuse non-toxic goitre evaluated by ultrasonic determination of thyroid volume. Clin Endocrinol (Oxf), 10:1-6, 1979.
26. Hansen J.M., Kampmann J.P., Perrrild H., Hegedus L.: Medical treatment of diffuse non-toxic goitre. Volumetric evalution of optimal treatment. In: Reinwein D., Scriva P.D. (eds). Treatment of endemic and sporadic goitre. Schattauer, Stuttgart, 149-152, 1985.
27. Hegedus L., Hansen J.M., Veiergang D., Karstrup S.: Does prophylactic thyroxine treatment afier operation for non-toxic goitre influence thyroid size? Br Med J, 294:801-803, 1987.
28. Hintze G., Emrich D., Kobberling J.: Therapy of endemic goitre: controlled study on the effect of iodine and thyroxine. Horm Metab Res, 17:362-365, 1985.
29. Ichikawa Y., Saito E., Abe Y. et al.: Presence of TSH receptors in thyroid neoplasms. J Clin Endocrinol Metab, 42:395-398, 1976.
30. Jarlov A.E., Nygard B., Hegedus S., Karstrup S., Hansen J.M.: Observer variation in ultrasound assessment of the thyroid gland. In Cooper D.S., (12).
31. Kopp P., Kimura E.T., Aeschimann S., Oestreicher M., Tobler A., Fey M.F., and Studer H.: Polyclonal and monoclonal thyroid nodules coexist within human multinodular goiters. J Clin Endocrinol Metab, 79:134-139, 1994.
32. Mandel S.J., Brent G., Larsen P.R.: Levothyroxine therapy in patients with thyroid disease. Ann Intern Med, 119:492-502, 1993.
33. Marcocci C, Golia F., Bruno-Bossio G., Vignali E., and Pinchera A.: Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women. J Clin Endocrinol Metab, 78:818-823, 1994.
34. Mazzaferri E.L.: Thyroid carcinoma: papillary and follicular. In: Endocrine Tumors blackwell scientific. Publications edited by E.L. Mazzaferri and N.A. Samman, 278-333, 1993.
35. Mazzaferri E.L.: Management of a solitary thyroid nodule. N Engl J Med, 328:553-559.
36. Mazzaferri E.L., Young R.L., Oertel J.E.: Papillary thyroid carcinoma: the impact of therapy in 576 patients. Medicine (Baltimore), 56:171-196, 1977.
37. Minuto F., Barreca A., Del Monte P., Cariola G., Torre G.C. and Giordano G.: Immunocreative insulin-like growth factor I (IGF-I) and IGF-binding protein content in human thyroid tissue. J Clin Endocrinol Metab, 68:621-626, 1989.
38. Molitch M., Beck J.R., Dreisman M., Gottlieb J.E., Pauker S.G.: The cold thyroid nodule: an anlysis of diagnostic and therapeutic options. Endocr Rev, 5: 185-199, 1984.
39. Molnar G.D., Colby M.Y. Jr., Woolner L. B.: Clinics on endocrine and metabolic diseases. 11. Demonstration of thyroid-stimulating-hormone dependence in a case of metastatic carcinoma of thyroid origin. Proc Staff Meet Mayo Clin, 38: 280, 2-288, 1963.
40. Morita T., Tamai H., Oshima A., Komaki G., Matsübayashi, Kuma K., Nakagawa T.: Changes in serum thyroid hormone, thyrotropin and thyrotropin and thyroglobulin concentrations during thyroxine therapy in patients with solitary thyroid nodules. J Clin Endocrinol Metab, 69:227-230, 1989.
41. Papini E., Bacci V., Panuzzi C, Pacella CM, Fabbrini R., Bizzarri G., Petrucci L., Gianmarco V., La Medica P., Masala M., Pitaro M., and Nardi F.: A prospective randomized trial of levothyroxine suppressive therapy for solitary thyroid nodules. Clin Endocrinol (Oxf.), 38:507-513, 1993.
42. Perrild H., Hansen J.M., Hegedus L., Rytter L., Holm B., Gundtofte E., Johansen K.: Triiodothyronine and thyroxine treatment of diffuse non-toxic goitre evaluated eb ultrasonic scanning. Acta Endocrinol (Copenh), 100:382-387, 1982.
43. Ramelli F., Studer H., Bruggisser D.: Pathogenesis of thyroid nodules in multinodular goiter. Am J Pathol, 109:215-223, 1982.
44. Reverter J.L., Lucas A., Salinas I., et al.: Suppressive therapy with levothyroxine for solitary thyroid nodules. Clin Endocrinol (Oxf), 36:25-28, 1992.
45. Ridgway E.C.: Clinician's evaluation of a solitary thyroid nodule. J Clin Endocrinol Metab, 74:231-235, 1992.
46. Roti E., Minelli R., Gardini E., and Braverman L.E.: The use and misuse of thyroid hormone. Endoc Rev, 14, 4:401-423, 1993.
47. Smith S.A., Gharib H.: Clinical uses of thyroid hormone. In: Advances in Endocrinology and Metabolism. Mazzaferri E.L., Bar R.S., Kreisberg R.A. Eds-Mosby St. Louis, 1994, 5:323-348.
48. Smith S.A., Gharib H.: Thyroid nodule suppression. In: Mazzaferri E.L. (ed) Advances in Endocrinology and Metabolism. Vol.2, St. Louis, 1991, 107-124.
49. Studer H. and Derwahl M.: Mechanisms of nonneoplastic endocrine hyperplasia. A changing concept: a review focused on the thyroid gland. Endocr Rev, 16, 4: 411-426, 1995.
50. Studer H. and Gerber H.: Nontoxic goiter. In: The thyroid gland. Raven Press, New York, 1990, pp 391-404.
51. Takahashi H., Jiang N-S., Gorman C.A. et al.: Thyrotropin receptors in normal and pathological human thyroid tissues. J Clin Endocrinol Metab, 47:870-876, 1978.
52. Thomas G.A., Williams D., Williams E.D.: The clonal origin of thyroid nodules and adenomas. Am J Pathol, 134:141-147, 1989.
53. Tunbridge W.M.G., Caldwell G.: The epidemiology of thyroid disease. In: Werner and Ingbars's: The thyrod Bravemann L.E., High R.D. Edit, Lippincott J.B. Co., Philadelphia, pag. 578-587, 1991.
54. Wartofsky L.: Does replacement thyroxine therapy cause osteoporosis?. Adv Endocrinol Metab, 4:157-175, 1993.
55. Weetman A.P., McGregor A.M.: Autoimmune thyroid disease: further developments in our understanding. Endocr Rev, 15:788-830, 1994.